Rituximab Administration and Reactivation of HBV-Reference-Cited by-同舟云学术

Rituximab Administration and Reactivation of HBV

Published:2010-12-01 Issue: Volume:2010 Page:1-8
ISSN:2090-1364
Container-title:Hepatitis Research and Treatment
language:en
Short-container-title:Hepatitis Research and Treatment

Author:

Tsutsumi Yutaka¹²,Ogasawara Reiki¹,Kamihara Yusuke¹,Ito Shinichi¹,Yamamoto Yoshiya³,Tanaka Junji⁴,Asaka Masahiro⁵,Imamura Masahiro⁴

Affiliation:

1. Department of Hematology, Hakodate Municipal Hospital, Hakodate 041-8680, Japan

2. Department of Internal Medicine, Hakodate Municipal Hospital, 1-10-1 Minato-Cho, Hakodate 041-8680, Japan

3. Department of Gastroenterology, Hakodate Municipal Hospital, Hakodate 041-8680, Japan

4. Department of Hematology and Oncology, Hokkaido University Graduate School of Medicine, Sapporo 060-8638, Japan

5. Department of Gastroentelology, Hokkaido University Graduate School of Medicine, Sapporo 060-8638, Japan

Abstract

Rituximab is a drug used for the treatment of B-cell non-Hodgkin's lymphoma, and its range of use has expanded to the treatment of collagen diseases such as idiopathic thrombocytopenic purpura and rheumatoid arthritis. One serious complication of rituximab use is the reactivation of dormant hepatitis B virus, and prevention of this phenomenon has become an urgent issue. This paper provides a general outline of the problem through an analysis of patient cases that we and other groups have experienced to date.

Publisher

Hindawi Limited

Subject

Hepatology

Link

http://downloads.hindawi.com/archive/2010/182067.pdf

Reference92 articles.

1. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

2. Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma

3. Re-Treatment of Relapsed Indolent B-Cell Lymphoma With Rituximab

4. Pure red cell aplasia due to parvovirus B19 in a patient treated with rituximab

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Update on Myositis Therapy: from Today’s Standards to Tomorrow’s Possibilities;Current Pharmaceutical Design;2021-11-15

2. Liver failure from delayed hepatitis B reactivation in anti-HBc-positive patient following rituximab for B-cell lymphoma;BMJ Case Reports;2021-07

3. B Cell Therapies, Approved and Emerging: a Review of Infectious Risk and Prevention During Use;Current Rheumatology Reports;2015-08-20

4. Hepatitis B virus reactivation with a rituximab-containing regimen;World Journal of Hepatology;2015

5. Beyond Tumor Necrosis Factor Inhibition: The Expanding Pipeline of Biologic Therapies for Inflammatory Diseases and Their Associated Infectious Sequelae;Clinical Infectious Diseases;2014-02-27